Here are the Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease? journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Is there no goddess, is there a stimulus check for 2025, their role, is there a generic for eliquis, is there school tomorrow, is there a tornado near me, is there a full moon tonight, the role of the holy spirit, the role for nasa, the role of tutoring in problem solving.
Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
Purpose of Review: Chronic kidney disease and end-stage kidney disease (ESKD) are well-established risk factors for cardiovascular disease (CVD), the leading cause of mortality in the dialysis population. Conventional therapies, such as statins, blood pressure control, and renin-angiotensin-aldosterone system blockade, have inadequately addressed this cardiovascular risk, highlighting the unmet need for effective treatment strategies. Sodium–glucose transporter 2 (SGLT2) inhibitors have demonstrated significant renal and cardiovascular benefits among patients with type 2 diabetes, heart failure, or CKD at risk of progression. Unfortunately, efficacy data in dialysis patients is lacking as ESKD was an exclusion criterion for all major clinical trials of SGLT2 inhibitors. This review explores the potential of SGLT2 inhibitors in improving cardiovascular outcomes among patients with ESKD, focusing on their direct cardiac effects. Recent Findings: Recent clinical and preclinica l studies have shown promising data for the application of SGLT2 inhibitors to the dialysis population. SGLT2 inhibitors may provide cardiovascular benefits to dialysis patients, not only indirectly by preserving the remaining kidney function and improving anemia but also directly by lowering intracellular sodium and calcium levels, reducing inflammation, regulating autophagy, and alleviating oxidative stress and endoplasmic reticulum stress within cardiomyocytes and endothelial cells. Summary: This review examines the current clinical evidence and experimental data supporting the use of SGLT2 inhibitors, discusses its potential safety concerns, and outlines ongoing clinical trials in the dialysis population. Further research is needed to evaluate the safety and effectiveness of SGLT2 inhibitor use among patients with ESKD. © The Author(s) 2024.
Authors : Siddiqui R.; Obi Y.; Dossabhoy N.R.; Shafi T.
Source : Springer
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1007/s11906-024-01314-3 |
| ISSN | 15226417 |
| Volume | 26 |
You can download the article here
If You have any problem, contact us here